Lupin has informed that it enclosed a Press release regarding launch of Varenicline Tablets, 0.5 mg and 1 mg, after having received approval from the US FDA. This may be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.
The above information is a part of company’s filings submitted to BSE.